Publicacións en colaboración con investigadores/as de University of Toronto (13)

2020

  1. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

    Current Therapeutic Research - Clinical and Experimental, Vol. 93

2017

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

2013

  1. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 1, pp. 83-88

2012

  1. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

  2. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2011

  1. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 404-413

  2. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Arthritis and Rheumatism, Vol. 63, Núm. 3, pp. 573-586

2010

  1. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637

2009

  1. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study

    Arthritis and Rheumatism, Vol. 60, Núm. 4, pp. 976-986

2008

  1. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients withd-heumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1365-1373

  2. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1360-1364

  3. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Arthritis Care and Research, Vol. 59, Núm. 10, pp. 1371-1377

2007

  1. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 2, pp. 143-150